Effect of BQ-123, an endothelin antagonist, on renal hemodynamics, tubular function, vasoactive hormones, and blood pressure in healthy humans: A dose response study

American Journal of Hypertension

Volumn 18, Issue 12, 2005, Pages 1578-1585

  Pedersen, Erling B ^a,b   Thomsen, Ingrid M ^a   Fjordside, Lene Sloth ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b HOLSTEBRO HOSPITAL   (Denmark)

Author keywords

Aldosterone; Angiotensin II; Atrial natriuretic peptide; Blood pressure; BQ 123; Brain natriuretic peptide; Endothelin; GFR; Renal blood flow; Renin; Sodium excretion; Vasopressin

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN RECEPTOR ANTAGONIST; LITHIUM; RENIN; SODIUM; VASOPRESSIN;

ADULT; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFUSION; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY PLASMA FLOW; KIDNEY TUBULE FUNCTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM EXCRETION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; KIDNEY TUBULES; MALE; PEPTIDES, CYCLIC; RECEPTOR, ENDOTHELIN A; RENAL CIRCULATION; RENIN; SODIUM; VASCULAR RESISTANCE;

EID: 29144519904     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.06.008     Document Type: Article

References (29)

1. W.G. Haynes, D.J. Webb Contribution of endogenous generation of endothelin-1 to basal vascular tone Lancet 344 1994 852 854
2. G. Sutsch, W. Kiowski, X.W. Yan, P. Hunziker, S. Christen, W. Strobel, J.H. Kim, P. Rickenbacher, O. Bertel Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure Circulation 98 1998 2262 2268
3. R.N. Channick, G. Simonneau, O. Sitbon, I.M. Robbins, A. Frost, V.F. Tapson, D.B. Badesch, S. Roux, M. Rainisio, F. Bodin, L.J. Rubin Effects of the dual endothelin-receptor antagonist BQ-123 in patients with pulmonary hypertension a randomised placebo-controlled study Lancet 358 2001 1119 1123
4. M.F. Hand, W.G. Haynes, D.J. Webb Reduced endogenous endothelin-1- mediated vascular tone in chronic renal failure Kidney Int 55 1999 613 620
5. C. Cardillo, C.M. Kilcoyne, M. Waclawiw, R.O. Cannon 3rd, J.A. Panza Role of endothelin in the increased vascular tone of patients with essential hypertension Hypertension 33 1999 753 758
6. J.C. Spratt, J. Goddard, N. Patel, F.E. Strachan, A.J. Rankin, D.J. Webb Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men Br J Pharmacol 134 2001 648 654
7. I. Anand, J. McMurray, J.N. Cohn, M.A. Konstam, T. Notter, K. Quitzau, F. Ruschitzka, T.F. Luscher EARTH investigators Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH) randomised, double-blind, placebo-controlled trial Lancet 364 2004 347 354
8. J.N. Bech, C.B. Nielsen, P. Ivarsen, K.T. Jensen, E.B. Pedersen Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans Am J Physiol 274 1998 F914 F923
9. E.B. Pedersen, H. Eiskjær, B. Madsen, H. Danielsen, M. Egeblad, C.B. Nielsen Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ration in patients with arterial hypertension and unilateral renal artery disease Nephrol Dial Transplant 8 1993 1064 1070
10. K.T. Jensen, J. Carstens, P. Ivarsen, E.B. Pedersen A new, fast and reliable radio immunoassay of brain natriuretic peptide in human plasma Reference values in healthy subjects and in patients with different diseases Scand J Clin Lab Invest 57 1997 529 540
11. E.B. Pedersen, H. Danielsen, E.S. Spencer Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension Eur J Clin Pharmacol 26 1984 543 547
12. S.S. Sorensen, J.K. Madsen, E.B. Pedersen Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers Am J Physiol 266 1994 F411 F418
13. K.A. Kaasjager, S. Shaw, H.A. Koomans, T.J. Rabelink Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans J Am Soc Nephrol 8 1997 32 39
14. L. Schmetterer, S. Dallinger, B. Bobr, N. Selenko, H.G. Eichler, M. Wolzt Systemic and renal effects of an ET(A) receptor subtype-specific antagonist in healthy subjects Br J Pharmacol 124 1998 930 934
15. J.L. Tycho Vuurmans, P. Boer, H.A. Koomans Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans Nephrol Dial Transplant 19 2004 2742 2746
16. A. Montanari, A. Biggi, N. Carra, M. Ziliotti, E. Fasoli, L. Musiari, P. Perinotto, A. Novarini Endothelin-A receptors mediate renal hemodynamic effects of exogenous angiotensin II in humans Hypertension 42 2003 825 830
17. A. Schmidt, M. Bayerle-Eder, H. Pleiner, C. Zeisner, M. Wolzt, G. Mayer, L. Schmetterer The renal and systemic hemodynamic effects of a nitric oxide-synthase inhibitor are reversed by a selective endothelin(a) receptor antagonist in men Nitric Oxide 5 2001 370 376
18. A. Montanari, A. Biggi, N. Carra, E. Fasoli, M. Calzolari, F. Corsini, P. Perinotto, A. Novarini Endothelin-A blockade attenuates systemic and renal hemodynamic effects of L-NAME in humans Hypertension 35 2000 518 523
19. H. Krum, R.J. Viskoper, Y. Lacourciere, M. Budde, V. Charlon Bosentan Hypertension Investigators The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension N Engl J Med 338 1998 784 790
20. W.G. Haynes, C.J. Ferro, K.P. O'Kane, D. Somerville, C.C. Lomax, D.J. Webb Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans Circulation 93 1996 1860 1870
21. R.C. Wimalasundera, S.A. McG Thom, L. Regan, A.D. Hughes Action of the endothelin receptor (ETA) antagonist BQ-123 on forearm blood flow in young normotensive subjects Clin Sci (Lond) 102 2002 661 666
22. A. Montanari, N. Carra, P. Perinotto, V. Iori, E. Fasoli, A. Biggi, A. Novarini Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man Hypertension 39 2002 715 720
23. J. Goddard, C. Eckhart, N.R. Johnston, A.D. Cumming, A.J. Rankin, D.J. Webb Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism J Am Soc Nephrol 15 2004 2601 2610
24. U. Campia, C. Cardillo, J.A. Panza Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients Circulation 109 2004 3191 3195
25. C. Cardillo, U. Campia, M. Iantorno, J.A. Panza Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients Hypertension 43 2004 36 40
26. J. Goddard, N.R. Johnston, M.F. Hand, A.D. Cumming, T.J. Rabelink, A.J. Rankin, D.J. Webb Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure a comparison of selective and combined endothelin receptor blockade Circulation 109 2004 1186 1193
27. H. Scholz, B.K. Kramer, M. Hamann, K.H. Gotz, A. Kurtz Effects of endothelins on renin secretion from rat kidneys Acta Physiol Scand 155 1995 173 182
28. T. Ritthaler, H. Scholz, M. Ackermann, G. Riegger, A. Kurtz, B.K. Kramer Effects of endothelins on renin secretion from isolated mouse renal juxtaglomerular cells Am J Physiol 268 1995 F39 F45
29. G.P. Rossi, C. Ganzaroli, M. Cesari, A. Maresca, M. Plebani, G.G. Nussdorfer, A.C. Pessina Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension Cardiovasc Res 57 2003 277 283